动态对比增强MR成像药代动力学参数预测肺癌脑转移治疗反应
前瞻性纳入44例肺癌患者共123个新诊断脑转移灶,基线和治疗后早期行DCE MRI测量药代动力学参数。基线参数与客观反应无关,早期ΔKtrans、Δve和Δvp与客观反应显著相关,Δve预测客观反应的AUC为0.93。
要点
- 基线DCE MRI药代动力学参数与脑转移瘤客观反应无关。
- 治疗后早期Δve是预测客观反应的最佳指标,AUC为0.93(95%CI 0.87,0.99)。
- 早期ΔKtrans和Δvp亦与客观反应显著相关(p=0.02)。
核心结论
- DCE MRI及早期Δve可能有助于预测肺癌患者脑转移瘤的客观反应。
研究设计与样本
- 前瞻性研究纳入44例肺癌患者共123个新诊断脑转移灶,基线和治疗后早期(7-10周)行3-T MRI及DCE MRI序列,中期(5-7个月)MRI用于判断客观反应。
诊断标准与关键数值
- 以中期MRI较基线的体积变化判断客观反应;早期Δve预测客观反应的AUC为0.93(95%CI 0.87,0.99);早期ΔKtrans、Δve和Δvp与客观反应显著相关(p分别为0.02、0.001、0.02)。
临床应用与阅片要点
- DCE MRI可预测肺癌脑转移瘤的治疗反应,早期Δve为最佳预测指标,可能用于个体化患者随访。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To determine the diagnostic accuracy of pharmacokinetic parameters measured by dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) in predicting the response of brain metastases to antineoplastic therapy in patients with lung cancer.
METHODS: Forty-four consecutive patients with lung cancer, harbouring 123 newly diagnosed brain metastases prospectively underwent conventional 3-T MRI at baseline (within 1 month before treatment), during the early (7-10 weeks) and midterm (5-7 months) post-treatment period. An additional DCE MRI sequence was performed during baseline and early post-treatment MRI to evaluate baseline pharmacokinetic parameters (K trans, k ep, v e, v p) and their early variation (∆K trans, ∆k ep, ∆v e, ∆v p). The objective response was judged by the volume variation of each metastasis from baseline to midterm MRI. ROC curve analysis determined the best DCE MRI parameter to predict the objective response.
RESULTS: Baseline DCE MRI parameters were not associated with the objective response. Early ∆K trans, ∆v e and ∆v p were significantly associated with the objective response (p = 0.02, p = 0.001 and p = 0.02, respectively). The best predictor of objective response was ∆v e with an area under the curve of 0.93 [95% CI = 0.87, 0.99].
CONCLUSIONS: DCE MRI and early ∆v e may be a useful tool to predict the objective response of brain metastases in patients with lung cancer.
KEY POINTS: • DCE MRI could predict the response of brain metastases from lung cancer • ∆v e was the best predictor of response • DCE MRI could be used to individualize patients' follow-up.
引用
- Kuchcinski G, Le Rhun E, Cortot AB, et al. Dynamic contrast-enhanced MR imaging pharmacokinetic parameters as predictors of treatment response of brain metastases in patients with lung cancer. Eur Radiol. 2017. PMID: 28210799. doi:10.1007/s00330-017-4756-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。